Markets:

Overview

News

Currencies

International

Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

59.45 +0.02 (+0.03%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

A Look Ahead: Biomarin Pharmaceutical's Earnings Forecast ↗

October 28, 2024

Via Benzinga

Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate

October 24, 2024

From Monopar Therapeutics Inc.

Via GlobeNewswire

Investors seeking growth at a reasonable cost should explore NASDAQ:BMRN. ↗

October 18, 2024

NASDAQ:BMRN is showing good growth, while it is not too expensive.

Via Chartmill

NASDAQ:BMRN appears to be flying under the radar despite its strong fundamentals. ↗

October 16, 2024

Investors should take notice ofBIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN)—it offers a great deal for the fundamentals it presents.

Via Chartmill

How Is The Market Feeling About Biomarin Pharmaceutical? ↗

October 15, 2024

Via Benzinga

Analyst Expectations For Biomarin Pharmaceutical's Future ↗

October 04, 2024

Via Benzinga

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $14,000 Today ↗

September 23, 2024

Via Benzinga

(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest ↗

September 10, 2024

Via Benzinga

Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients ↗

October 09, 2024

The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential...

Via Benzinga

3 Oversold Stocks with Big RSI Rebound Potential

October 03, 2024

Everybody loves finding a bargain or getting a good deal, and it's no different when it comes to stocks. The RSI indicator is a great way to find them.

Via MarketBeat

Topics Economy

Investors should take note of NASDAQ:BMRN, a growth stock that remains attractively priced. ↗

September 26, 2024

Despite its growth, BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) remains within the realm of affordability.

Via Chartmill

BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish ↗

September 25, 2024

BioMarin Pharmaceutical aims to achieve $4 billion in revenue by 2027, driven by Voxzogo adoption, despite emerging competition from Ascendis Pharma. Goldman Sachs maintains a "Buy" rating with a $139...

Via Benzinga

(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest ↗

August 21, 2024

Via Benzinga

Beyond The Numbers: 11 Analysts Discuss Biomarin Pharmaceutical Stock ↗

August 20, 2024

Via Benzinga

Investors should take notice of NASDAQ:BMRN—it offers a great deal for the fundamentals it presents. ↗

September 25, 2024

BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), an undervalued stock with good fundamentals.

Via Chartmill

Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? ↗

September 22, 2024

10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90%

Via Benzinga

GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

September 17, 2024

Via Benzinga

Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term ↗

September 16, 2024

BioMarin stock dips in response to TransCon CNP data, as analysts note TransCon CNP could challenge BioMarin's Voxzogo by late 2025 due to its dosing schedule and potential safety benefits.

Via Benzinga

Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug ↗

September 16, 2024

The companies could soon face off in the growth treatment market for children with a genetic disorder.

Via Investor's Business Daily

FDA Battles Backlog of Drug Factory Inspections Since COVID-19 ↗

September 06, 2024

FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.

Via Benzinga

BioMarin Restructures, Outlines Roadmap To $4B Revenues By 2027 ↗

September 05, 2024

BioMarin aims for $4 billion revenue by 2027, focusing on gene therapy and enzyme treatments, with a robust pipeline set to enhance growth.

Via Benzinga

Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (14 Ratings) ↗

September 05, 2024

Via Benzinga

Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In ↗

September 04, 2024

Ascendis Pharma reported disappointing Q2 sales of $38.76 million, missing the consensus of $92.7 million. Key updates included a higher-than-expected U.S. price for Yorvipath and a delayed cash flow...

Via Benzinga

NASDAQ:BMRN is showing good growth, while it is not too expensive. ↗

September 04, 2024

Investors should take note ofBIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), a growth stock that remains attractively priced.

Via Chartmill

Wall Street's Top 10 Stock Calls This Week - Saturday, Aug. 24 ↗

August 24, 2024

What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Aug. 19-23, 2024.

Via Talk Markets

Palo Alto Networks To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

August 20, 2024

Via Benzinga

NASDAQ:BMRN is not too expensive for the growth it is showing. ↗

August 14, 2024

While growth is established for BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), the stock's valuation remains reasonable.

Via Chartmill

$1000 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today ↗

August 07, 2024

Via Benzinga

Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts Cost For Hemophilia A Gene Therapy; Lifts Annual Guidance ↗

August 06, 2024

BioMarin Pharmaceutical shifts focus to commercial operations for Roctavian in the U.S., Germany, and Italy. Projected cost reductions aim to achieve profitability by 2025. Strong Q2 performance driven...

Via Benzinga

Yum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On Tuesday ↗

August 06, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.